Dmitry Gabrilovich : Peregrine Pharmaceuticals KOL :
..... MDSC's....MDSC's....MDSC's.... its becoming apparent that Dmitry Gabrilovich went with Peregrine Pharmaceuticals because they have Bavituximab (PS Targeting) which reduces MDSC's in a significant way and what happens after is astronomical, in that it helps create an optimal immune response.
Ask yourself why Dmitry went with Peregrine?
Ask yourself why all the sabotage attempts?
I believe I know the answer of so many questions and if a simple landscaper can figure it out.... so can you.
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
Vincenzo Bronte, Sven Brandau, Shu-Hsia Chen, Mario P. Colombo, Alan B. Frey, Tim F. Greten, Susanna Mandruzzato, Peter J. Murray, Augusto Ochoa, Suzanne Ostrand-Rosenberg, Paulo C. Rodriguez, Antonio Sica, Viktor Umansky, Robert H. Vonderheide & Dmitry I. Gabrilovich
Received 04 November 2015 Accepted 02 June 2016 Published 06 July 2016
Myeloid-derived suppressor cells (MDSCs) have emerged as major regulators of immune responses in cancer and other pathological conditions. In recent years, ample evidence supports key contributions of MDSC to tumour progression through both immune-mediated mechanisms and those not directly associated with immune suppression. MDSC are the subject of intensive research with >500 papers published in 2015 alone. However, the phenotypic, morphological and functional heterogeneity of these cells generates confusion in investigation and analysis of their roles in inflammatory responses. The purpose of this communication is to suggest characterization standards in the burgeoning field of MDSC research. .. .. Since the inception of this term, interest in MDSC has blossomed. MDSCs are implicated in various aspects of immune regulation in diseases that involve chronic inflammation, especially cancer, but also infection, autoimmune diseases, trauma, graft versus host disease and so on. Recently, evidence of the clinical significance of MDSC in cancer has emerged. Therefore, despite realization that the term ‘MDSC’ may not be optimal, we feel that it is purposeful and should be retained to assure consistency as the field continues to develop.
.. ..
These authors contributed equally to this work. Vincenzo Bronte & Dmitry I. Gabrilovich
Affiliations
Department of Medicine, University Hospital, University of Verona, Verona 37134, Italy Vincenzo Bronte Department of Otorhinolaryngology, University Hospital Essen, Essen D-45122, Germany Sven Brandau Department of Oncological Sciences, Tisch Cancer Institute, Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA Shu-Hsia Chen Department of Experimental Oncology and Molecular Medicine, Molecular Immunology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 20133, Italy Mario P. Colombo New York University School of Medicine, New York, New York 10029, USA Alan B. Frey GI-Malignancy Section, Thoracic and GI Oncology Branch, NCI, Bethesda, Maryland 20892, USA Tim F. Greten Department of Surgery, Oncology and Gastroenterology, Section of Oncology and Immunology, University of Padova, Padova 35128, Italy Susanna Mandruzzato Veneto Institute of Oncology IOV-IRCCS, Padova 35128, Italy Susanna Mandruzzato Departments of Infectious Diseases and Immunology, St Jude Children’s Research Hospital, Memphis, Tennessee 38105, USA Peter J. Murray Stanley S. Scott Cancer Center, Louisiana State University, New Orleans, Louisiana 70112, USA Augusto Ochoa University of Maryland Baltimore County, Baltimore, Maryland 21250, USA Suzanne Ostrand-Rosenberg Georgia Regents University Cancer Center, Augusta, Georgia 30912, USA Paulo C. Rodriguez Humanitas Clinical and Research Center, Via Manzoni 56, Rozzano, Milan 20089, Italy Antonio Sica Department of Pharmaceutical Sciences, Università del Piemonte Orientale ‘Amedeo Avogadro’, via Bovio 6, Novara 20089, Italy Antonio Sica Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg 69120, Germany Viktor Umansky Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim 69120, Germany Viktor Umansky Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA Robert H. Vonderheide Translational Tumor Immunology, The Wistar Institute, Philadelphia, Pennsylvania 19104, USA Dmitry I. Gabrilovich
Contributions
V.B. and D.I.G. designed the concept of the review, edited and summarized the contributions of other authors and wrote the paper. S.B., S.-H.C., M.P.C., A.B.F., T.F.G., S.M., P.J.M., A.O., S.O.-R., P.C.R., A.S., V.U. and R.H.V. wrote the paper. Competing financial interests
The authors declare no competing financial interests.
"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical pipeline." -- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!
AI
